Literature DB >> 27736762

eis Promoter C14G and C15G Mutations Do Not Confer Kanamycin Resistance in Mycobacterium tuberculosis.

Suporn Pholwat1, Suzanne Stroup1, Scott Heysell1, Oleg Ogarkov2,3, Svetlana Zhdanova2, Girija Ramakrishnan1, Eric Houpt4.   

Abstract

We studied the significance of particular eis mutations on Mycobacterium tuberculosis drug resistance using a specialized transduction strategy. Recombinant strains harboring eis promoter mutations C14T, C12T, and G10A exhibited kanamycin resistance with MICs of 40, 10, and 20 μg/ml, respectively, while recombinant strains harboring C14G and C15G mutations were kanamycin susceptible (MIC, 2.5 to 5 μg/ml). Each of the eis mutants tested remained amikacin susceptible (MIC, 0.5 to 4 μg/ml). The identification of specific eis mutations is needed for accurate genotypic susceptibility testing for kanamycin.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27736762      PMCID: PMC5119041          DOI: 10.1128/AAC.01775-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges.

Authors:  Giovanni Battista Migliori; Alberto Matteelli; Daniela Cirillo; Madhukar Pai
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-03       Impact factor: 2.471

2.  Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis.

Authors:  M Analise Zaunbrecher; R David Sikes; Beverly Metchock; Thomas M Shinnick; James E Posey
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

3.  Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains.

Authors:  Florence Brossier; David Guindo; Anne Pham; Florence Reibel; Wladimir Sougakoff; Nicolas Veziris; Alexandra Aubry
Journal:  J Clin Microbiol       Date:  2016-04-06       Impact factor: 5.948

4.  Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.

Authors:  Ann Sturdy; Anna Goodman; Ricardo J José; Angela Loyse; Marie O'Donoghue; Onn Min Kon; Martin J Dedicoat; Thomas S Harrison; Laurence John; Marc Lipman; Graham S Cooke
Journal:  J Antimicrob Chemother       Date:  2011-06-03       Impact factor: 5.790

5.  Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.

Authors:  Courtney E Maus; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Microevolution of extensively drug-resistant tuberculosis in Russia.

Authors:  Nicola Casali; Vladyslav Nikolayevskyy; Yanina Balabanova; Olga Ignatyeva; Irina Kontsevaya; Simon R Harris; Stephen D Bentley; Julian Parkhill; Sergey Nejentsev; Sven E Hoffner; Rolf D Horstmann; Timothy Brown; Francis Drobniewski
Journal:  Genome Res       Date:  2012-01-31       Impact factor: 9.043

7.  Real-time PCR using mycobacteriophage DNA for rapid phenotypic drug susceptibility results for Mycobacterium tuberculosis.

Authors:  Suporn Pholwat; Beeta Ehdaie; Suporn Foongladda; Kimberly Kelly; Eric Houpt
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

8.  Undertreated HIV and drug-resistant tuberculosis at a referral hospital in Irkutsk, Siberia.

Authors:  S K Heysell; O B Ogarkov; S Zhdanova; E Zorkaltseva; S Shugaeva; J Gratz; S Vitko; E D Savilov; M E Koshcheyev; E R Houpt
Journal:  Int J Tuberc Lung Dis       Date:  2016-02       Impact factor: 2.373

Review 9.  Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review.

Authors:  Sophia B Georghiou; Marisa Magana; Richard S Garfein; Donald G Catanzaro; Antonino Catanzaro; Timothy C Rodwell
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

10.  Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRsl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study.

Authors:  Elisa Tagliani; Andrea M Cabibbe; Paolo Miotto; Emanuele Borroni; Juan Carlos Toro; Mikael Mansjö; Sven Hoffner; Doris Hillemann; Aksana Zalutskaya; Alena Skrahina; Daniela M Cirillo
Journal:  J Clin Microbiol       Date:  2015-07-15       Impact factor: 5.948

View more
  5 in total

1.  Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.

Authors:  Florence Brossier; Anne Pham; Christine Bernard; Alexandra Aubry; Vincent Jarlier; Nicolas Veziris; Wladimir Sougakoff
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

2.  Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex.

Authors:  Roger Vargas; Luca Freschi; Andrea Spitaleri; Sabira Tahseen; Ivan Barilar; Stefan Niemann; Paolo Miotto; Daniela Maria Cirillo; Claudio U Köser; Maha R Farhat
Journal:  Antimicrob Agents Chemother       Date:  2021-08-30       Impact factor: 5.938

3.  Melting the eis: Nondetection of Kanamycin Resistance Markers by Routine Diagnostic Tests and Identification of New eis Promoter Variants.

Authors:  Serej D Ley; Samantha Pillay; Elizabeth M Streicher; Yuri F van der Heijden; Frederik Sirgel; Brigitta Derendinger; Marianna de Kock; Sébastien Gagneux; Robin M Warren; Grant Theron; Margaretha de Vos
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

4.  Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.

Authors:  Syed Beenish Rufai; Kulsum Umay; Praveen Kumar Singh; Sarman Singh
Journal:  PLoS One       Date:  2020-03-04       Impact factor: 3.240

5.  New epidemic cluster of pre-extensively drug resistant isolates of Mycobacterium tuberculosis Ural family emerging in Eastern Europe.

Authors:  Viacheslav Sinkov; Oleg Ogarkov; Igor Mokrousov; Yuri Bukin; Svetlana Zhdanova; Scott K Heysell
Journal:  BMC Genomics       Date:  2018-10-22       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.